Stock News & Analysis

Axon Enterprise looks well-positioned for a comeback.

Competitors are vying for an increasing share of this lucrative industry.

The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors.

Arista is a highly profitable networking supplier, while Axon is a fast-growing technology provider in public safety.

Oracle is just trying to protect itself against the risk that Jupiter won't be built.

One comeback took around a month. Another took nearly six years. Which one should a holder plan for?

Nike is dealing with slumping sales while Procter & Gamble's profitability is soaring, a stark divergence that reshapes the growth-versus-stability trade-off.

Two years into a four-year plan to build a massive data center in New Mexico, Oracle is already claiming force majeure.

AMC generates negative free cash flow, while Roblox is experiencing monetization headwinds.

CEO Kathy Warden sees "unprecedented levels of demand" for the company's military technology.

Anthropic's IPO could be one of the biggest events for the stock market this year.

Airbnb's 20% net margin and asset-light model command a premium valuation, while DICK'S Sporting Goods trades at a fraction of that multiple despite strong FY 2025 growth.

The memory maker has strung together two straight triple-digit years just once before. What came next?

It crushed analyst estimates for third-quarter profitability.

Berkshire has always run a concentrated approach in its stock portfolio.

Which chipmaker has the most riding on the ChatGPT maker's ability to pay?

The financial data and analytics specialist published its latest quarterly earnings report.

What comes next for this space and defense company?

Two days before it's set to report third-quarter earnings, the company announced a new acquisition.

Game sales are booming.